DIMERIX LTD

0.250

0.000

Volume:810.81K

Turnover:201.58K

Market Cap:150.10M

PE:-5.03

High:0.255

Open:0.250

Low:0.245

Close:0.250

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.56

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-10.17

PE(LYR):-5.03

Loading ...

Overview Company News Filings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/DXB.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.25,"timestamp":1789107120000,"preClose":0.25,"halted":0,"volume":810805,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Closed","change":0,"latestTime":"09-11 16:12:00 AEST","open":0.25,"high":0.255,"low":0.245,"amount":201578,"amplitude":0.04,"askPrice":0.25,"askSize":115024,"bidPrice":0.245,"bidSize":25000,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.25,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.560555,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.25,"auctionPrice":0.25,"auctionVolume":7021,"auctionTime":1789106991055,"referencePrice":0.25,"referenceTime":1789108920634,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106991055}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.560555,"shares":600396776,"dividePrice":0,"high":0.255,"amplitude":0.04,"preClose":0.25,"low":0.245,"week52Low":0.157,"pbRate":"-10.17","psRate":"23.62","week52High":0.665,"institutionHeld":0,"latestPrice":0.25,"committee":-0.642918,"eps":-0.0497,"divideRate":0,"volume":810805,"delay":0,"ttmEps":-0.0497,"open":0.25,"prevYearClose":0.55,"prevWeekClose":0.285,"prevMonthClose":0.28,"prevQuarterClose":0.205,"fiveDayClose":0.285,"twentyDayClose":0.295,"sixtyDayClose":0.225,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619805884","title":"Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2619805884","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619805884?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:14","pubTimestamp":1773627284,"startTime":"0","endTime":"0","summary":"Dimerix  is set to conduct a blinded review of the ACTION3 phase three study data to confirm statistical assumptions of the primary endpoint during March, according to a Monday Australian bourse filing.It will use methods specified in the study's statistical analysis plan previously submitted to the US Food and Drug Administration .The phase 3 Action3 trial is a placebo-controlled study of the efficacy and safety of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker. It is designed to capture evidence of proteinuria reduction and kidney function during the trial, aimed at generating sufficient evidence to support marketing approval.The FDA previously confirmed that the proposed primary endpoint of percent reduction in proteinuria compared to placebo is suitable to support traditional approval of DMX-200 via the 505 pathway, with estimated glomerular fil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","DXB.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484775","title":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484775?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:07","pubTimestamp":1773623244,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical AssumptionsMarch 16 (Reuters) - Dimerix Ltd DXB.AX:DIMERIX TO CONDUCT REVIEW OF ACTION3 STATISTICAL ASSUMPTIONSFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","DXB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619485692","title":"Dimerix Ltd - Dimerix to Conduct Review of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485692?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:29","pubTimestamp":1773610167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618600488","title":"Dimerix Completes Patient Dosing in Phase 3 Kidney Disease Trial; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600488","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600488?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:52","pubTimestamp":1773114760,"startTime":"0","endTime":"0","summary":"Dimerix  said the phase 3 Action3 trial of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis completed dosing the last adult patient recruited into the study, bringing the final enrollment to 333 adult patients, according to a Tuesday Australian bourse filing.Focal segmental glomerulosclerosis is a kidney disease characterized by progressive scarring in parts of the glomeruli, leading to proteinuria, progressive loss of kidney function, and often end-stage renal disease.The study is closed to further recruitment of adult patients, while the recruitment of pediatric patients remains ongoing as an independent group in the trial, the filing said.The full two-year study will assess the efficacy and safety of DMX-200 in focal segmental glomerulosclerosis patients when dosed in combination with standard-of-care blood pressure medication known as an angiotensin II receptor blocker over two years, per the filing. It is expected to be completed in March 2028.The com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":44,"code":"91000000","status":"200"}]}}